Acute Interstitial Nephritis Medical Services in China

Acute Interstitial Nephritis (AIN) is an immune-mediated inflammatory disorder primarily affecting the renal interstitium and tubules, leading to abrupt deterioration in kidney function. Characterized by interstitial edema, inflammatory cell infiltration (predominantly lymphocytes, eosinophils, and plasma cells), and tubular injury, AIN typically presents with acute kidney injury (AKI), often accompanied by systemic symptoms such as fever, rash, arthralgia, and peripheral eosinophilia—collectively termed the 'classic triad' (though present in only ~10–15% of cases). Pathogenesis involves T-cell–driven hypersensitivity reactions triggered by exogenous antigens—most commonly medications—including NSAIDs, proton pump inhibitors (PPIs), antibiotics (e.g., beta-lactams, fluoroquinolones), and diuretics. Less frequently, AIN arises from autoimmune conditions (e.g., Sjögren’s syndrome, systemic lupus erythematosus), infections (e.g., streptococcal, Legionella, H. pylori), or idiopathic causes. The inflammatory cascade results in tubulointerstitial damage, impaired solute transport, and reduced glomerular filtration rate (GFR), sometimes progressing to chronic kidney disease if diagnosis or intervention is delayed. Epidemiologically, AIN accounts for 10–15% of all biopsy-proven AKI cases in adults and is more prevalent among older adults (median age 60–70 years), with a slight male predominance. Drug-induced AIN represents over 70% of cases, with PPIs now surpassing NSAIDs as the most common offending agents in many cohorts. Key risk factors include polypharmacy, advanced age, preexisting chronic kidney disease, and genetic susceptibility (e.g., HLA-DRB1*07:01 allele linked to PPI-associated AIN). Importantly, early recognition is critical: untreated AIN may lead to irreversible fibrosis and permanent renal impairment. Quality of life is significantly impacted—not only due to fatigue, nausea, fluid retention, and cognitive fog associated with uremia but also from prolonged diagnostic uncertainty, treatment-related side effects (e.g., corticosteroid-induced insomnia, hyperglycemia, mood changes), and occupational or social disruption during recovery. Patients often experience anxiety about long-term kidney health, dialysis dependency, and medication restrictions. Timely discontinuation of the inciting agent and initiation of immunosuppression markedly improve outcomes; however, residual renal dysfunction occurs in ~20–40% of patients, necessitating ongoing nephrology follow-up and lifestyle modification. Multidisciplinary support—including dietary counseling, psychological services, and patient education on drug safety—is integral to holistic management and sustained functional recovery.

Acute interstitial nephritis (AIN) is an immune-mediated inflammatory disorder of the renal interstitium, commonly triggered by medications (e.g., NSAIDs, PPIs, antibiotics such as beta-lactams or fluoroquinolones), infections, or systemic autoimmune diseases. It accounts for approximately 10–15% of cases of acute kidney injury (AKI) requiring renal biopsy and presents with nonspecific symptoms including fatigue, fever, rash, arthralgia, and oliguria, often accompanied by sterile pyuria, eosinophiluria, and mild proteinuria. Prompt diagnosis—typically confirmed via renal biopsy showing interstitial edema, lymphoplasmacytic infiltration, and tubulitis—is critical to prevent progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD).

Conservative treatment forms the cornerstone of early management. Immediate discontinuation of the suspected offending agent is mandatory and often sufficient to induce spontaneous recovery in mild-to-moderate cases. Hydration status must be carefully optimized: euvolemia should be maintained without inducing volume overload, particularly in patients with reduced glomerular filtration rate (GFR). Electrolyte imbalances—including hyperkalemia, metabolic acidosis, and hyponatremia—require vigilant monitoring and targeted correction. In cases of significant AKI, temporary renal replacement therapy (RRT)—such as intermittent hemodialysis or continuous venovenous hemofiltration—may be necessary to manage life-threatening complications (e.g., severe hyperkalemia, pulmonary edema, or uremic encephalopathy) while awaiting renal recovery. Nutritional support emphasizing low-sodium, low-potassium, and moderate-protein intake is advised during the acute phase to reduce metabolic stress on recovering tubules.

Pharmacologic intervention is indicated when clinical or histopathologic evidence suggests persistent or progressive inflammation despite drug withdrawal. Glucocorticoids remain the primary immunosuppressive therapy. Prednisone 0.5–1.0 mg/kg/day (maximum 60 mg/day) is typically initiated orally for 2–4 weeks, followed by a slow taper over 4–8 weeks based on clinical response, serum creatinine trajectory, and urine sediment analysis. In severe cases—such as those with rapidly deteriorating GFR (>50% decline within 72 hours), extensive interstitial fibrosis on biopsy, or crescent formation—pulse intravenous methylprednisolone (500–1000 mg/day for 3 consecutive days) may precede oral tapering. Emerging evidence supports adjunctive use of mycophenolate mofetil (MMF) in steroid-resistant or relapsing AIN, particularly in autoimmune-associated variants; however, MMF is not routinely recommended as first-line due to limited randomized data. Rituximab has been reported in isolated case series for refractory, autoantibody-positive AIN but lacks robust clinical trial validation. Importantly, corticosteroid initiation should be weighed against infection risk, glycemic control, bone health, and gastrointestinal tolerance—especially in elderly or comorbid patients.

Surgical treatment has no role in the routine management of AIN. Renal biopsy—though minimally invasive—is the only procedural intervention routinely performed and serves strictly diagnostic and prognostic purposes. It is not therapeutic. Nephrectomy, dialysis access surgery, or other surgical interventions are contraindicated unless required for unrelated indications (e.g., vascular access placement in patients progressing to ESRD after failed recovery). No surgical modality alters the natural history or inflammatory cascade of AIN.

China offers distinct advantages in the multidisciplinary management of AIN. First, high-volume tertiary hospitals—particularly those affiliated with major academic centers such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—maintain standardized, biopsy-driven diagnostic pathways with rapid turnaround times (<72 hours for light/electron microscopy and immunofluorescence). Second, integrated traditional Chinese medicine (TCM) co-management is available in select centers, where evidence-informed herbal formulations (e.g., modified Huang Qi Tang or Shen Fang Bai Zhu San) are used adjunctively to ameliorate steroid side effects and support tubular repair—though these are always administered under nephrology supervision and never as monotherapy. Third, China’s national drug safety surveillance system (CNDA Adverse Reaction Monitoring Center) enables real-time pharmacovigilance, facilitating earlier recognition of regional AIN outbreaks linked to specific medications (e.g., widespread PPI use). Finally, cost-effective access to generic corticosteroids and RRT, coupled with streamlined referral networks between community hospitals and specialized renal centers, ensures timely escalation of care without prohibitive financial burden.

Recovery advice emphasizes longitudinal monitoring and preventive education. Patients should undergo serial assessment of serum creatinine, estimated GFR, urinary sediment, and electrolytes at 1, 3, 6, and 12 months post-diagnosis—even if initial recovery appears complete—as up to 20% develop residual CKD or late-onset hypertension. Urinary biomarkers (e.g., NGAL, KIM-1) are increasingly utilized in research settings to detect subclinical tubular injury but remain investigational for routine follow-up. Patients must receive explicit counseling to avoid re-exposure to the inciting agent and cross-reactive drugs (e.g., avoiding all PPIs after omeprazole-induced AIN); a personalized medication safety card is recommended. Lifestyle modifications include maintaining normotension (<130/80 mmHg), avoiding NSAIDs and herbal nephrotoxins (e.g., aristolochic acid-containing herbs), and annual influenza/pneumococcal vaccination to mitigate infection-related relapse triggers. For patients with persistent eGFR <60 mL/min/1.73m² beyond 6 months, referral to a CKD clinic for comprehensive risk factor management—including SGLT2 inhibitor consideration if albuminuria is present—is warranted. Psychosocial support is integral: studies from Chinese cohorts indicate that structured nurse-led education programs significantly improve medication adherence and reduce 1-year readmission rates for AIN-related AKI. Ultimately, successful recovery hinges not only on acute immunosuppression but on sustained, patient-centered vigilance to preserve long-term renal parenchymal integrity.